Cardiovascular News’ top 10 most popular stories of December 2021

726

The most read stories from December 2021 include analysis of the CHEETAH study and the role of mechanical aspiration thrombectomy in conjunction with percutaneous coronary intervention (PCI), highlights from PCR London Valves (21–23 November, London, UK and virtual), and a study suggesting a potential role for machine learning in predicting outcomes for patients with coronary artery disease.

“Tantalising” data open the door for further study of mechanical aspiration thrombectomy with PCI

Results of the CHEETAH clinical study highlight the potential role of mechanical aspiration thrombectomy in conjunction with percutaneous coronary intervention (PCI) in native coronary arteries in patients with high thrombus burden according to the study’s principal investigator, Jay Mathews (Manatee Memorial Hospital, Bradenton, USA). Mathews spoke to Cardiovascular News following the presentation of the study’s findings at the Transcatheter Cardiovascular Therapeutics annual meeting (TCT 2021, 4–6 November, Orlando, USA and virtual).

US physicians “among nation’s first” to implant neurostimulator technology for advanced heart failure

Doctors at St David’s Medical Center in Austin, USA implanted a new neurostimulator technology in patients to help treat advanced heart failure—and are among the first physicians in the USA to do so, according to a press release.

Robocath announces completion of first robotic coronary angioplasty with R-One in China

Robocath announced the successful completion of what it has described as the first coronary angioplasty in China assisted by its R-One robotic platform. The procedure took place at the 301 Hospital in Beijing on 24 November, performed by Yundai Chen.

“Encouraging” early results for TEER seen in bRIGHT registry

The first analysis of findings from the bRIGHT registry, detailing real-world results of tricuspid edge-to-edge repair (TEER) at 30 days in 200 patients indicate that the Triclip (Abbott) transcatheter device was safe and effective at reducing tricuspid regurgitation. Philipp Lurz (Leipzig, Germany), who presented the findings at PCR London Valves (21–23 November, London, UK and virtual), discusses insights from the study.

Machine learning predicts 10-year risk of death in patients with suspected or known coronary artery disease

The likelihood of patients with suspected or known coronary artery disease dying within 10 years, can be more accurately predicted using a novel artificial intelligence (AI) score, compared to established scores used by health professionals worldwide. This is according to the authors of research presented at EuroEcho 2021 (9–11 December, virtual).

FDA clears CavaClear IVC filter removal laser sheath

Royal Philips announced US Food and Drug Administration (FDA) de novo clearance for the Philips inferior vena cava (IVC) filter removal laser sheath—CavaClear—to remove an IVC filter when previous methods of removal have failed.

AI-based algorithm could predict outcomes after cardiac surgery

A novel artificial intelligence (AI) algorithm that identifies a cardiac dysfunction from a single-lead electrocardiogram (ECG) can also predict long-term patient survival after cardiac surgery, according to new research from Mayo Clinic (Rochester, USA).

First clinical data backs use of Jenavalve TAVI system in patients with aortic regurgitation

First clinical results of transcatheter aortic valve implantation (TAVI) using the Jenavalve system (Jenavalve) in patients with severe aortic regurgitation show that the device is safe and efficient in high-risk patients, significantly improves New York Heart Association (NYHA) classification.

First clinical results for Tria biopolymer valve published

Foldax announced publication of the first clinical results for its Tria biopolymer heart valve, which the company describes as the first polymer valve to be implanted in humans.

Sapien 3 with Alterra present gains FDA approval

Edwards Lifesciences received approval from the US Food and Drug Administration (FDA) for the use of the Edwards Sapien 3 transcatheter valve with the Alterra adaptive prestent—Sapien 3 with Alterra—for patients with severe pulmonary regurgitation.

 


LEAVE A REPLY

Please enter your comment!
Please enter your name here